Plasma fractionation and protein therapy manufacturing at scale
Prothya Biosolutions operates a plasma-to-therapeutics manufacturing footprint processing ~3 million liters annually. The tech stack is operationally mature—heavy on Siemens automation (Step 7, TIA Portal), SAP (including SuccessFactors and modules for warehouse/PM), and analytical instrumentation (HPLC, SDS-PAGE)—but shows no adopting or replacing signals, suggesting stable, compliance-locked infrastructure. Hiring velocity is accelerating across manufacturing and quality (16 of 35 active roles), with notable Clinical Development and Quality Director searches, indicating scale-up in both production throughput and regulatory capability.
Notable leadership hires: Clinical Development Lead, Quality Director
Prothya Biosolutions manufactures plasma-derived medicinal products and protein therapeutics, formed in 2021 from the merger of Plasma Industries Belgium (with roots in the Belgian Red Cross) and Sanquin Plasma Products. The company processes approximately 3 million liters of plasma annually and produces stable plasma derivatives including clotting factors, immunoglobulins, and albumin solutions. Headquartered in Brussels, the company operates as a contract manufacturer and development partner for international pharmaceutical firms. With 1,001–5,000 employees across manufacturing, quality, engineering, and clinical functions, Prothya is expanding global presence through active hiring in Belgium, Netherlands, Canada, Peru, and the United States.
Prothya manufactures plasma-derived medicinal products including clotting factors, immunoglobulins, and albumin solutions, processed from ~3 million liters of plasma annually for international pharmaceutical partners.
Prothya is headquartered in Neder-Over-Heembeek, Brussels, Belgium, and currently hiring across Belgium, Netherlands, Canada, Peru, and the United States.
Prothya Biosolutions's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.